Abstract
No public abstract is available from the verified source records.
Sarwan K. Bishnoi, Kenneth B. Pittman, Susan Yeend, Michael Paul Brown, Dusan Kotasek, W. K. Patterson, Amanda Rose Townsend, C. Lüke, Timothy Jay Price
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cancer of unknown primary site
2008
Metastases of undetermined source
10.1016/s0147-0272(79)80019-7 · 1979
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study
10.1200/jco.2000.18.17.3101 · 2000
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study
10.1200/jco.20.6.1651 · 2002
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
10.1080/02841860510029554 · 2005
Epidemiology of unknown primary tumours: incidence and population based survival of 1285 patients in southeast Netherlands, 1984–1992
10.1016/s0959-8049(01)00378-1 · 2002
Unresolved referenced work
Kept as external metadata until matched
Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden
10.1002/cncr.10593 · 2002
Unresolved referenced work
2000
Diagnostic and therapeutic management of cancer of an unknown primary
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
10.1016/s0959-8049(03)00547-1 · 2003
Probing the unknown in cancer of unknown primary: which way is the right way?
10.1093/annonc/mdp609 · 2010
Low serum albumin levels and liver metastases are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
10.1002/cncr.22300 · 2006
New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis
10.1016/j.clon.2008.09.007 · 2009
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study
10.1038/sj.bjc.6603440 · 2006
Carcinoma of unknown primary site: treatment with 1-h paclitaxel, carboplatin, and extended-schedule etoposide
10.1200/jco.1997.15.6.2385 · 1997
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin
10.1023/a:1008369812295 · 2000
Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial
10.1097/ppo.0b013e3181c6aa89 · 2010
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis
10.1016/j.ctrv.2009.05.005 · 2009
Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan
10.1007/s10147-006-0599-9 · 2006
Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
10.1038/sj.bjc.6604829 · 2009
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network
10.1200/jco.2006.09.3047 · 2007
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
10.1200/jco.2003.12.104 · 2003
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study
10.1002/cncr.22379 · 2006
A randomized trial of cisplatin with or without gemcitabine in patients with carcinoma of an unknown primary and without poor prognostic factors: results of the GEFCAPI02 trial
2008
Can baseline complete geriatric assessment (CGA) predict toxicity in elderly non-small cell lung cancer (NSCLC) patients (pts) receiving combination chemotherapy? Results from the first 100 pts in the prospective multicenter NVALT-3 study
2007
Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population based study
10.1002/(sici)1097-0142(19980601)82:11<2123::aid-cncr6>3.0.co;2-w · 1998
10.1200/jco.2005.02.527
10.1200/jco.2005.02.527 · 2005
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site
10.1200/jco.2002.04.019 · 2002
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature
10.1200/jco.2007.10.6583 · 2007
Polypharmacy in the elderly. Early intervention can prevent complications
1997
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer
10.2165/00002512-200219010-00003 · 2002
Are the elderly underrepresented in clinical drug trials?
10.1177/009127009903901101 · 1999
No additional external references are available.